High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
BACKGROUND
Immune checkpoint-inhibitors targeting the PD-1/PD-L1 system are FDA approved in microsatellite instable (MSI) or mismatch repair deficient (dMMR) colorectal cancer (CRC). PD-L1 expression is tightly linked to features connected to immune checkpoint inhibitor response, but studies on large subsets of cancers analyzing the correlation between different status of MSI/dMMR, tumor infiltrating lymphocytes and PD-L1 expression are still lacking.


METHODS
More than 1800 CRC were analyzed for PD-L1 by immunohistochemistry in a tissue microarray format. Data were compared to MMR, the number of intratumoral CD8+ cytotoxic T-cells, and adverse clinico-pathological parameters. Different cutoff levels for defining PD-L1 positivity in tumor cells (1%, 5%, 10%, and 50%) yielded comparable results.


RESULTS
At a cutoff level of 5%, PD-L1 positivity was seen in 5.1% of tumors. PD-L1 was more often positive in dMMR (18.6%) than in MMR proficient (pMMR) cancers (4.1%; p < 0.0001). The number of intratumoral CD8+ lymphocytes was strikingly higher in PD-L1 positive (939.5 ± 118.2) than in PD-L1 negative cancers (310.5 ± 24.8). A higher number of intratumoral CD8+ lymphocytes was found in dMMR CRC (PD-L1 positive: 1999.7 ± 322.0; PD-L1 negative: 398.6 ± 128.0; p < 0.0001) compared to pMMR CRC (PD-L1 positive: 793.2 ± 124.8; PD-L1 negative: 297.2 ± 24.2; p < 0.0001). In dMMR and pMMR CRC, PD-L1 expression in tumor cells was unrelated to tumor stage, lymph node status or lymphatic/venous invasion. PD-L1 positivity in tumor associated immune cells was seen in 47.5% of cases and was significantly linked to high numbers of tumor infiltrating CD8+, low tumor stage, and absence of lymph node metastasis and lymphatic/venous invasion (p < 0.0001 each).


CONCLUSION
The data support the previously suggested fact that PD-L1 expression in tumor cells is driven by extensive cytotoxic T-cell infiltration in highly immunogenic dMMR and pMMR CRC. Frequent and intense PD-L1 expression in tumor cells of dMMR CRC may contribute to the high response rates of dMMR CRC to immune checkpoint-inhibitors.
['Möller|Katharina|K|', 'Blessin|Niclas C|NC|', 'Höflmayer|Doris|D|', 'Büscheck|Franziska|F|', 'Luebke|Andreas M|AM|', 'Kluth|Martina|M|', 'Hube-Magg|Claudia|C|', 'Zalewski|Katarzyna|K|', 'Hinsch|Andrea|A|', 'Neipp|Michael|M|', 'Mofid|Hamid|H|', 'Lárusson|Hannes|H|', 'Daniels|Thies|T|', 'Isbert|Christoph|C|', 'Coerper|Stephan|S|', 'Ditterich|Daniel|D|', 'Rupprecht|Holger|H|', 'Goetz|Albert|A|', 'Bernreuther|Christian|C|', 'Sauter|Guido|G|', 'Uhlig|Ria|R|', 'Wilczak|Waldemar|W|', 'Simon|Ronald|R|', 'Steurer|Stefan|S|', 'Minner|Sarah|S|', 'Burandt|Eike|E|', 'Krech|Till|T|', 'Perez|Daniel|D|', 'Izbicki|Jakob R|JR|', 'Clauditz|Till S|TS|', 'Marx|Andreas H|AH|']
D060890:B7-H1 Antigen D015179:Colorectal Neoplasms D053843:DNA Mismatch Repair D006801:Humans D053842:Microsatellite Instability D013602:T-Lymphocytes, Cytotoxic
PD-L1 colorectal cancer tissue microarray CD8+ T-cell lymphocytes